Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA4 | P22748 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.31 |
| ▸ | SHBG | P04278 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34468142 | 1.00 | KMT2A (0.39) | KMT2ACA1CA2CA4TDP1 | |
| SCHEMBL34468143 | 1.00 | KMT2A (0.39) | KMT2ACA1CA2CA4TDP1 | |
| SCHEMBL6586974 | 1.00 | KMT2A (0.39) | KMT2ACA1CA2CA4TDP1 | |
| SCHEMBL6587704 | 0.96 | — | — | |
| SCHEMBL10741709 | 0.93 | ACHE (0.37) | KMT2ACA1CA2CA4TDP1 | |
| SCHEMBL25676962 | 0.93 | ACHE (0.37) | KMT2ACA1CA2CA4TDP1 | |
| SCHEMBL132918 | 0.88 | — | — | |
| SCHEMBL10306742 | 0.88 | — | — | |
| SCHEMBL601777 | 0.88 | — | — | |
| SCHEMBL22878856 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 259 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3986438-B1 | P53 ACTIVATOR PEPTIDOMIMETIC MACROCYCLES | MERCK SHARP & DOHME LLC (US) | 2025-04-16 | — | — | EP | disclosed |
| US-20250042961-A1 | P53 PEPTIDOMIMETIC MACROCYCLES | AGENCY FOR SCIENCE TECHNOLOGY AND RESEARCH (SG) | 2025-02-06 | — | — | US | disclosed |
| US-20250034211-A1 | C-TERMINAL EXTENDED P53 ACTIVATOR CROSSLINKED PEPTIDOMIMETIC MACROCYCLES AGAINST MDM2/MDMX | MERCK SHARP & DOHME LLC (US) | 2025-01-30 | — | — | US | disclosed |
| CN-118829648-A | P53 peptidomimetic macrocycles | 默沙东有限责任公司 | 2024-10-22 | — | — | CN | disclosed |
| EP-4444740-A2 | P53 PEPTIDOMIMETIC MACROCYCLES | Merck Sharp & Dohme LLC (US) | 2024-10-16 | — | — | EP | disclosed |
| EP-4441067-A1 | C-TERMINAL EXTENDED P53 ACTIVATOR CROSSLINKED PEPTIDOMIMETIC MACROCYCLES AGAINST MDM2/MDMX | Merck Sharp & Dohme LLC (US) | 2024-10-09 | — | — | EP | disclosed |
| WO-2024197199-A2 | TARGETING PRAC1 IN STEROID HORMONE DRIVEN CANCER | FRED HUTCHINSON CANCER CENTER (US) | 2024-09-26 | — | — | WO | disclosed |
| US-20240124518-A1 | METHODS FOR PREPARING PURIFIED POLYPEPTIDE COMPOSITIONS | AILERON THERAPEUTICS INC (US) | 2024-04-18 | — | — | US | disclosed |
| EP-3126375-B1 | MACROCYCLIC PEPTIDOMIMETICS FOR ALPHA-HELIX MIMICRY | UNIV ROCHESTER (US) | 2023-12-13 | — | — | EP | disclosed |
| WO-2023107353-A2 | P53 PEPTIDOMIMETIC MACROCYCLES | MERCK SHARP & DOHME LLC (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2009126292-A2 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2009-10-15 | — | — | WO | disclosed |
| EP-2094721-A1 | BIS-SULFHYDRYL MACROCYCLIZATION SYSTEMS | Aileron Therapeutics, Inc. (US) | 2009-09-02 | — | — | EP | disclosed |
| WO-2009099677-A2 | THERAPEUTIC PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090088553-A1 | Bis-Sulfhydryl Macrocyclization Systems | AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) | 2009-04-02 | — | — | US | disclosed |
| US-20090047711-A1 | BIS-SULFHYDRYL MACROCYCLIZATION SYSTEMS | AILERON THERAPEUTICS, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20080262200-A1 | Triazole Macrocycle Systems | AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) | 2008-10-23 | — | — | US | disclosed |
| WO-2008104000-A2 | TRIAZOLE MACROCYCLE SYSTEMS | AILERON THERAPEUTICS, INC. (US) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008076904-A1 | BIS-SULFHYDRYL MACROCYCLIZATION SYSTEMS | AILERON THERAPEUTICS, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| US-4644089-A | CONVERTING ALKANES TO AROMATICS WITH A VANADIUM OXIDE-ALUMINUM PHOSPHATE CATALYST | PHILLIPS PETROLEUM COMPANY (US) | 1987-02-17 | — | — | US | disclosed |
| US-4607129-A | DIVANADIUM PENTOXIDE AND SILICA AS CATALYST | PHILLIPS PETROLEUM COMPANY (US) | 1986-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262200-A1 | Triazole Macrocycle Systems | FLT3, VIP, NGLY1 | KMT2A 2989/4885CA1 1908/4885CA2 3450/4885 |
| US-20090088553-A1 | Bis-Sulfhydryl Macrocyclization Systems | CBS, HLCS, CTH | KMT2A 4532/4885CA1 2044/4885CA2 2681/4885 |
| US-20090047711-A1 | BIS-SULFHYDRYL MACROCYCLIZATION SYSTEMS | CBS, HLCS, CTH | KMT2A 4532/4885CA1 2044/4885CA2 2681/4885 |
| US-20240124518-A1 | METHODS FOR PREPARING PURIFIED POLYPEPTIDE COMPOSITIONS | VIP, NGLY1, IAPP | KMT2A 4570/4885CA1 2090/4885CA2 3327/4885 |
| US-20250034211-A1 | C-TERMINAL EXTENDED P53 ACTIVATOR CROSSLINKED PEPTIDOMIMETIC MACROCYCLES AGAINST MDM2/MDMX | TP53, MDM4, MDM2 | KMT2A 2429/4885CA1 1715/4885CA2 4144/4885 |
| US-20250042961-A1 | P53 PEPTIDOMIMETIC MACROCYCLES | TP53, MDM2, MDM4 | KMT2A 4593/4885CA1 2252/4885CA2 4440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.